Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | SELP | P16109 | 1/20 | 0.30 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23854196 | 1.00 | CA14 (0.38) | CA14MEN1KMT2ACA12CA2 | |
| SCHEMBL934416 | 1.00 | CA14 (0.38) | CA14MEN1KMT2ACA12CA2 | |
| SCHEMBL4547485 | 0.89 | CA14 (0.38) | CA14MEN1KMT2ACA12CA2 | |
| SCHEMBL17881260 | 0.82 | MEN1 (0.40) | CA14MEN1KMT2ACA12CA2 | |
| SCHEMBL21385385 | 0.82 | MEN1 (0.40) | CA14MEN1KMT2ACA12CA2 | |
| SCHEMBL13345432 | 0.81 | MAPT (0.33) | CA14MEN1KMT2ACA12CA2 | |
| SCHEMBL3899118 | 0.80 | REN (0.40) | CA14MEN1KMT2ACA12CA2 | |
| SCHEMBL13598307 | 0.80 | REN (0.40) | CA14MEN1KMT2ACA12CA2 | |
| SCHEMBL18248185 | 0.80 | REN (0.40) | CA14MEN1KMT2ACA12CA2 | |
| SCHEMBL20593366 | 0.80 | CA14 (0.38) | CA14MEN1KMT2ACA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404245-B2 | Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof | ROTTAPHARM BIOTECH S.R.L. (IT) | 2025-09-02 | — | — | US | disclosed |
| US-20250136620-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4126821-B1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | Rottapharm Biotech Srl (IT) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023137225-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230127805-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-04-27 | — | — | US | disclosed |
| EP-3885339-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | Rottapharm Biotech S.r.l. (IT) | 2021-09-29 | — | — | EP | disclosed |
| CN-102471314-B | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM SPA | 2015-05-13 | — | — | CN | disclosed |
| CN-102471314-A | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM SPA | 2012-05-23 | — | — | CN | disclosed |
| US-7115624-B1 | Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2006-10-03 | — | — | US | disclosed |
| EP-1214324-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2006-06-14 | — | — | EP | disclosed |
| US-6410556-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | disclosed |
| EP-1214324-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019830-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404245-B2 | Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof | BACH1, ADH1C, ADH1A | CA14 1408/4885MEN1 1742/4885KMT2A 436/4885 |
| US-20230127805-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | BACH1, ADH1C, ADH1A | CA14 1408/4885MEN1 1742/4885KMT2A 436/4885 |
| US-20250136620-A1 | BTK DEGRADER | BTK, CBL, LYN | CA14 4242/4885MEN1 2462/4885KMT2A 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.